All PlansCoverageMedium impact
Cardiac Hemodynamic Monitoring for the Management of Heart Failure in the Outpatient Setting
Blue Cross & Blue Shield of Mississippi·MS · Cardiology, Internal Medicine, Family Medicine·Medical Policy
We identified it
Jun 20, 2026
Summary
This new policy establishes that all cardiac hemodynamic monitoring devices for outpatient heart failure management (including implantable pressure sensors, thoracic bioimpedance devices, inert gas rebreathing, and Valsalva maneuver devices) are considered investigational and not covered. This affects billing for these specialized monitoring technologies in ambulatory and outpatient settings.
Action Required
Immediately: Billing team must verify that any claims for outpatient cardiac hemodynamic monitoring devices are flagged as investigational/non-covered services. Review current patients using CardioMEMS, Cordella PA sensors, thoracic bioimpedance devices (BioZ, Zoe, Cheetah Starling SV, PhysioFlow, ReDS, etc.), or VeriCor systems to ensure proper patient financial responsibility discussions occur. Update billing system to flag these services for patient payment or alternative coverage verification.